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Introduction:  Regional  and  hospital  decision-makers  increasingly  require  analyses  assessing  the  cost-
beneﬁt  proﬁle  of  new  cancer  drugs.  This  analysis  evaluates  the  cost-beneﬁt  proﬁle  of nano  albumin-bound
paclitaxel  (nab-paclitaxel)  in  pancreatic  cancer,  versus  other  drugs  indicated  in high-unmet  need  solid
tumour indications  in  Nordic  countries  (Sweden,  Denmark,  Finland,  Norway  and  Sweden).
Methods:  For  a selected  number  of cancer  dugs,  approved  for metastatic  cancer  or non-curable  treatment
intention  patients  by  the  European  Medicine  Agency  (EMA)  after  2000,  and  indicated  in high-unmet
need  solid  tumours  (deﬁned  as  OS  in  ﬁrst  line  for trial comparator  ≤12  months),  a regression  analysis
was  conducted.  Overall  treatment  costs  of  cancer  drugs,  divided  by OS  and  PFS  months,  were related  to
the  clinical  improvement  offered  versus  trial  comparator.
Results: Eleven  of  42  drugs  (26.2%)  with  at least  one  indication  in solid  tumours  met inclusion  criteria.
On  average,  a  good  (R2 = 0.5359)  ﬁt between  costs  per  OS  month  and  OS  relative  beneﬁt  versus  trial
comparator  was  observed.  Nab-paclitaxel  offered  an  OS  improvement  of +27%  versus  trial  comparator
(average  improvement:  +31%),  at a cost  per  OS  month  of D  1,684  (average  cost:  D  2,247).  Correlation
between  costs  per  PFS  month  and  relative  PFS  beneﬁt  versus  trial comparator  was  still  observed,  but the
2goodness  of ﬁt was lower  (R = 0.1853)  than  for the  OS  analysis.
Conclusion:  Treatment  costs  of  new  cancer  therapies  should  reﬂect  their clinical  value, consistently  among
different  indications  with  comparable  characteristics.  Nab-paclitaxel,  recently  approved  in pancreatic
cancer,  showed  a similar  cost  per  OS or PFS  month  ratio  compared  to  other drugs  for high-unmet  need
solid tumours.
© 2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
In the last two decades many cancer treatments have been
eveloped to offer prolonged survival to patients with metastatic
ancer. These new treatments have signiﬁcantly improved survival
f certain cancers [1]. However, there are still certain types of high
nmet need advanced and/or metastatic tumors, associated with
oor prognosis and a median survival less than a year, for which
herapies have added only modest numerical increase in survival.
ung, pancreatic, liver, and gastric cancer, certain forms of aggres-
∗ Corresponding author. Fax: +358 9 471 74201.
E-mail address: pia.osterlund@hus.ﬁ (P. Osterlund).
ttp://dx.doi.org/10.1016/j.jcpo.2015.12.003
213-5383/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
sive breast cancer and melanoma, are only some examples of such
high unmet need conditions [2–5]. On parallel, the costs of cancer
treatments are increasing rapidly [6,7]. From a policy-making per-
spective, this means that increasing economic efforts are required
to fund the use of more effective and/or less toxic therapies [8].
In a context where the economic resources are limited, there is a
need of respecting budget constraints and consequently decisions
on budget allocation become extremely difﬁcult to take [9,10].
Policy makers, budget holders, and physicians as well, have the
responsibility of deciding how to allocate the assigned budget,
taking into account the clinical situation of the patients, and the
economic sustainability of the system. To ﬁnd a balance for these
two contrasting drivers, decision makers in all the healthcare sys-
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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em levels must be provided with the necessary information both
rom a clinical and an economical perspective.
In particular, there is a relevant need to deﬁne objective method-
logies comparing the cost-effectiveness of drugs in oncology. The
ypical questions for health economists are: “At certain price con-
itions, is drug X cost-effective vs. drug Y, for a given cancer?”
nd “Is this cost-effectiveness of drug X acceptable?” A number of
obust methodologies exist to address these question, ranging from
ost-effectiveness analysis to cost-utility analysis, using progres-
ion free survival, overall survival, quality adjusted survival (with
ALYs, quality adjusted life years) as main outcomes [11–13]. Com-
on  problems with these analyses are that they are cumbersome
nd need extensive data of quality of life, further line treatments,
nd end of life costs for the analysis. At the time of decision these
ata are often missing and QALYs are impossible to analyze [14].
owever, policy makers and budget holders, have other difﬁcult
uestions to answer, that are beyond the one-to-one comparison
n a single disease: “cost of drug X in cancer A is aligned to cost
f drug Y in cancer B, in a way that the cost of both drugs reﬂect
heir own value”? This question is crucial for those public or private
nstitutions ensuring that investments must be consistent across
onditions, in order to avoid access inequalities.
A simple and easy-to-use method should be developed to facili-
ate the decision makers in determining how to allocate the budget
or such serious diseases. For this purpose, the present study aims to
uggest a method to compare innovative therapies for high unmet-
eed solid tumours, considering their drug costs in relation with
heir clinical beneﬁts.
This article represents an attempt to deﬁne a method to address
his issue. More speciﬁcally, this method was used to compare the
conomic value of nano-albumin bound paclitaxel (nab-paclitaxel,
ecently approved by the European Medicines Agency in pancreatic
ancer) [15,16], versus other therapies approved in high-unmet-
eed solid tumours. The analysis correlates the cost of treatment of
 group of drugs approved for high-unmet need cancer types, with
he additional overall survival (OS) and progression free survival
PFS) beneﬁts provided by the drugs.
. Methods
This analysis aims to evaluate the cost proﬁle of nano-albumin
ound paclitaxel (nab-paclitaxel) in pancreatic cancer versus other
herapies in high-unmet need solid tumour indications. The anal-
sis was performed for four Nordic countries (Norway, Sweden,
enmark and Finland) using the health care funder’s perspective.
n this analysis treatment costs of drugs were related to their clin-
cal beneﬁt, expressed as absolute efﬁcacy (cost per month of PFS
nd OS) and relative efﬁcacy versus trial comparator (% PFS and OS
onths gained).
.1. Drug selection
Data regarding the drugs’ clinical efﬁcacy (comparator, treat-
ent duration, PFS, OS), posology, co-administration of other
ancer therapies (i.e. chemotherapy) and duration of treatment was
etrieved from the European Medicine Agency (EMA) website [17],
sing European Public Assessment Reports (EPARs). Where clinical
ata was not available, a supplementary published literature search
as performed to ﬁll the gap [see Table 1 for references].
The drug searches were performed on March 1st, 2015. Forhis analysis, we included drugs which: (i) had received the EMA
pproval after 2000; (ii) had been authorized in at least one
etastatic cancer indication; (iii) were indicated in a high unmet
eed condition (hereby deﬁned as a condition for which the drugcer Policy 7 (2016) 12–22 13
comparator in the registration trial achieved a maximum OS of 12
months).
2.2. Posology and duration of treatment
In order to calculate cost of cancer treatments, standard posol-
ogy, as reported in EPARs (and relative clinical trials), was  used.
Calculation of posology was  determined assuming to treat a hypo-
thetical patient of 65 Kg, with body surface area (BSA) of 1.73 m2.
Duration of treatment was  retrieved from EPARs, and if not avail-
able in the EPARs, from relative published literature [see Table 1 for
references].
For those treatment cases in which the amount of active sub-
stance exceeded the required posology, the amount of exceeding
drug was assumed wasted. For example, if a certain treatment in a
hypothetical patient required 2.8 vials, costs were calculated con-
sidering 3 vials, assuming that the remaining amount of drug (0.2
vials) could not be used to treat another patient. Duration of treat-
ment was assumed to be equal to that observed in the clinical trial
settings.
2.3. Costs
The total cost of each treatment was calculated using pharmacy
purchasing price for Denmark [18], Norway [19] and Sweden [20],
and wholesaler prices for Finland [21] (which are comparable to
pharmacy prices in the other countries). For Finland, wholesaler
prices were calculated multiplying the public prices reported in the
ofﬁcial source [21] by a coefﬁcient used to convert public prices into
wholesaler prices [extrapolated from [22]].
Prices were converted from local currencies to Euros (using
average exchange rates over the period January-March 2015, 3
months: 1 Danish Crown: D 0.1340; 1 Norwegian Crown: D 0.1139;
1 Swedish Crown: D 0.1090 [23]). For those therapies having mul-
tiple packaging and/or doses, same amount of therapy could be
associated to different treatment costs. In this case, the lowest cost
achievable was  used for the analysis.
Costs of drugs given in association with the study drug (e.g.
gemcitabine, co-administered to nab-paclitaxel, or cisplatin, co-
administered to S-1) were included in the analysis. Finally, the total
cost per patient was  obtained for each treatment and for all the
Nordic countries in analysis.
2.4. Tumor incidence data
Epidemiology data regarding incident tumor cases (in 2012,
latest update) was retrieved for each analyzed Nordic country to
estimate the size of the populations that could be treated, and to
estimate the related economic impact [24]. The number of diag-
nosed cases (which took into account whether the therapy was
indicated in a speciﬁc subgroup of patients, e.g. human epider-
mal  growth factor receptor 2 [HER2] positive gastric cancer for
trastuzumab and BRAF mutated in melanoma for vemurafenib) was
then transformed in crude incidence rates (expressed number of
cases per 100,000 inhabitants), using population data of the Nordic
countries [25]. Crude incidence rates were ﬁnally used in correla-
tion graphs (x–y scatterplots), where the size of the dots associated
to a drug/condition was  proportional to tumor incidence. The sum-
mary of tumor crude incidence rates is shown in Table 2.
2.5. AnalysesWith this analysis, we aimed to examine whether the incremen-
tal beneﬁt provided by a drug, versus its trial comparator, predicted
the monthly cost per OS/PFS month achieved. Costs per OS and
PFS month (or TTP month if PFS was  not available) were calculated
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Table 1
Drugs’ data collected from European Public Assessment Reports.
Therapy Indication (year of
EMA  approval)
Posology of study drug Duration of treatment Approved drug used in
combination
Posology of the approved
drug  used in combination
Comparator OS
(months)
OS
compar.
(months)
OS relative
beneﬁt (%)
PFS
(months)
PFS
compar.
(months)
PFS
relative
beneﬁt (%)
Bevacizumab Lung (2007) 7.5 or 15 mg/kg every
3  weeks + carboplatin/
paclitaxel
7.0 cycles (4.9
months)  [39]
Carboplatin/paclitaxel Paclitaxel: 200  mg/m2
Carboplatin:  AUC = 6.0
Both  drugs given once of
every  3-week cycle for up
to  6 cycles
Platinum-based
chemotherapy
and carboplatin
12.3 10.3 19.4%  6.4  4.8 33.3%
Cetuximab  Head and neck (2004) LD: 400 mg/m2 MD:
250  mg/m2, every
week
18 weekly cycles (4.2
months)  [40]
Cisplatin or
carboplatin + 5-ﬂuorouracil
Cisplatin: 100 mg/m2
5-ﬂuorouracil:
1,000  mg/m2 [41],
co-administered to
cetuximab
Cisplatin or
carboplatin plus
5-ﬂuorouracil
10.1 7.4 36.5%  5.6  3.3 69.7%
Erlotinib  Pancreas (2006) 100 mg once daily or
150  mg once daily
3.6 months (daily
treatment) [42,43]
Gemcitabine Gemcitabine:
1,000 mg/m2, Cycle
1—Days 1,  8, 15, 22, 29,  36
and  43  of an 8  week cycle;
Cycle  2 and subsequent
cycles—Days  1, 8  and 15 of
a  4  week cycle
Gemcitabine
alone
6.4 6.0 6.7%  3.8  3.6 5.6%
Ipilimumab  Melanoma (2011) 3  mg/kg every 4 weeks 4.0 cycles
(ﬁxed amount of
cycles;  2.8 months)
[44]
– – –  10.1  6.4 57.8%  2.9  2.8 3.6%
Nab-Paclitaxel  Pancreas (2014) 125 mg/m2 on Days 1,
8,  and 15 of each
28-day  cycle
4.2 cycles
(3.9  months)
[15,16]
Gemcitabine Gemcitabine:
1,000 mg/m2,
co-administered to
nab-paclitaxel
Gemcitabine
alone
8.5 6.7 26.9%  5.5  3.7 48.6%
Pemetrexed  Mesothelioma (2004) 500 mg/m2, every 3
weeks
6.0  cycles
(4.2 months) [45]
Cisplatin Cisplatin: 75 mg/m2, after
completion  of pemetrexed
infusion
Cisplatin alone 12.1  9.3 30.1% 5.7  3.9 46.2%
Ramucirumab
(combination)
Stomach  (2014) 8  mg/kg, on days 1  and
15  of each 28 day cycle
4.6 cycles (4.4
months)  [35]
Paclitaxel Paclitaxel: 80 mg/m2, on
days  1, 8 and 15 of a 28 day
cycle
Paclitaxel alone 9.6  7.4 29.7%  4.4  2.9 51.7%
Ramucirumab
(monotherapy)
Stomach  (2014) 8  mg/kg, every 2
weeks
4.8 cycles (2.1
months)  [35]
– – –  5.2  3.8 36.8%  2.1  1.3 61.5%
S-1  Stomach (2011) 25 mg/m2, twice daily
for  21 days, every 4
weeks
4.0 cycles (3.7
months)  [46]
Cisplatin Cisplatin: 75 mg/m2,
on  Days 1  through 5
repeated  every 4  weeks
Cisplatin 8.6  7.9 8.9%  4.8  5.5 -12.7%
Temsirolimus  Kidney (2007) 25 mg once weekly 17.0 cycles (4.0
months)  [47]
– – –  10.9  7.3 49.3%  3.8  1.9 100.0%
Trastuzumab  Stomach (2009) LD: 8 mg/kg ; MD:
6  mg/kg every 3 weeks
8.0 cycles (5.6
months)  [48]
Chemotherapy
(capecitabine or
5-ﬂuorouracil and
cisplatin)
Capecitabine:
1,000 mg/m2, twice daily
for  14 days every 3 weeks
for  6 cycles.
5-ﬂuorouracil:
800  mg/m2/day given
every  3  weeks for 6  cycles
Capecitabine or
5-ﬂuorouracil
and  cisplatin
13.8 11.1 24.3%  6.7  5.5 21.8%
Vemurafenib  Melanoma (2012) 960 mg twice daily 3.1 months (daily
treatment) [34,49,50]
– – Dacarbazine 13.6  9.7 40.2% 6.9  1.6 318.9%
Note: AUC = area under the curve. LD = loading dose. MD:  maintenance dose. The analysis only includes treatments approved for newly diagnosed (ﬁrst-line) patients, with the exception of ramucirumab, which is indicated
after  disease progression with chemotherapy [35]. Nevertheless, ramucirumab clinical data from second-line randomized trials were included as this therapy is indicated in a high-unmet need condition (gastric cancer) with
a  <12 months OS expectation for treatment-naïve patients (cfr S-1 and trastuzumab).
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ividing the overall cost of treatment (drug costs over the entire
eriod) by the number of months of OS and PFS achieved with the
reatment, respectively.
Second, a linear regression analysis was performed (overall and
y country) in order to evaluate dependency of cost per OS/PFS
onth on incremental beneﬁt achieved. The incremental beneﬁt
as expressed as the relative improvement in OS/PFS achieved with
he treatment, compared to its trial alternative. Robust regression
as evaluated to test goodness of ﬁt. For those cases with poor R2
<0.5), determined by observations with high leverages and resid-
als, a robust regression was attempted to re-calculate R2. Robust
eighted regression excluded observations with >0.25 Cook dis-
ance and weighted the remaining observations according to their
esidual distances from the means.
Since treatment costs could be affected by patients’ character-
stics, a simple sensitivity analysis, based on variations of ±10%
ody surface area (BSA) and ±10% weight, compared to the base
ase assumption (BSA = 1.73 m2; weight: 65 Kg), was  performed to
est analysis conclusions. Additional sensitivity analyses were con-
ucted to evaluate results under the assumption of absence of drug
astage.
Analyses were performed for each country, and then aggregated
alculating mathematical averages
. Results
From EMA database, 42 drugs with at least one indication in
olid tumours within 20 years were detected. Eleven of these
26.2%), met  the selection criteria and were included in the anal-
sis (Fig. 1): bevacizumab in non-small cell lung cancer (NSCLC),
etuximab in head and neck cancer (HNC), erlotinib in pancreatic
ancer (PancC); ipilimumab in melanoma, nab-paclitaxel in PancC,
emetrexed in mesothelioma, ramucirumab in gastric cancer (orcer Policy 7 (2016) 12–22 15
gastro-oesophageal junction) cancer, used as both in monotherapy
and in combination; S-1 (tegafur/gimeracil/oteracil) in gastric can-
cer (GC); temsirolimus in renal cell carcinoma (RCC), trastuzumab
in HER2 positive GC and vemurafenib in BRAF V600 mutation-
positive melanoma (BRAF melanoma).
Table 1 reports the information extracted from EPARs
[15,26–35] and from published clinical trials [see Table 1 for ref-
erences], which was used to calculate treatment costs and related
outcomes. Except for three therapies (temsirolimus, ipilimumab
and vemurafenib), the remaining agents are administered in com-
bination with chemotherapy and compared versus chemotherapy
alone (i.e. tested as add-on therapy trials). Only ipilimumab is
administered up to the maximum number of cycles (N = 4), while
the remaining therapies are discontinued at time of intolerance or
disease progression. Median PFS and OS in the comparator arm
(proxy of disease prognosis with standard, alternative options)
were 3.5 and 7.4 months, respectively, conﬁrming the high level
of unmet clinical needs for these conditions
Table 3 reports the overall drug costs of the chosen thera-
pies (including costs of drugs given in association, if any) in the
Nordic countries. Small variability of average costs by country
was observed (range: D 21,844–D 22,799), but it was not statisti-
cally signiﬁcant (test F for variance: 0.9243). On the other side,
internal cost variability was high (average of the four countries:
D 1,761–D  66,243) with S-1 and erlotinib being the less expensive
treatments, and ipilimumab and vemurafenib the most expensive
ones. Economic impact of chemotherapies given in association to
the study drugs was not negligible, especially for erlotinib, and
nab-paclitaxel, which are co-administered with gemcitabine.
Tables 4 and 5 show results of the cost per OS and PFS months
gained respectively. Considering the average of the four Nordic
countries, the drug associated with the lowest cost per OS was  S-1
(D 205 per OS month gained), while the one with the highest was
ipilimumab, (D 6,642 per OS month gained). The same trends were
observed for all countries and for PFS, too. Average costs of nab-
paclitaxel were D 1,684 per month of OS gained and D 2,602 per
month of PFS gained. Figs. 2 and 3 show results of the regression
analyses between cost per OS and PFS, respectively, and relative
clinical beneﬁts achieved versus trial comparator (Figs. 4 and 5
show results of correlation between costs and absolute beneﬁt vs.
trial comparator). Drugs positioned below the regression line had
a cost-beneﬁt proﬁle more advantageous than the average. Anal-
ysis shows that drugs with higher relative beneﬁt had generally
higher costs per OS or PFS gained. A good prediction was found for
OS (R2 = 0.5359). For PFS analysis, linear regression was associated
to poor ﬁt (R2 < 0.01). This was driven by two observations: ipili-
mumab  (high residual) whose cost per PFS month was higher than
the mean monthly costs, considered its relatively low PFS advan-
tage, and vemurafenib (high leverage), whose PFS effect was higher
than the mean, considered its cost. When robust regression was
performed to minimize the effects of these unexpected observa-
tions, R2 improved (0.1853), but remained much lower than for
OS analysis. In both analyses, nab-paclitaxel was found not above
regression lines, indicating that its cost was, at least, aligned to the
clinical value offered
Analysis of individual countries led to similar results for costs
per OS and PFS month as shown in Figs. 6 and 7. Overall, results
indicated that the overall cost of treatment for a drug reﬂected
much better the OS endpoint achievement, rather than the PFS
achievement.
Finally, one-way sensitivity analysis conducted on BSA and
weight demonstrated some variability of results depending on
patient’s characteristics (Table 6). For drugs administered at ﬁxed
doses (temsirolimus, ipilimumab, vemurafenib) costs remained
equal. Among drugs administered according to BSA or weight, treat-
ment costs (and consequentially costs per OS and PFS) changed,
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Table 2
Tumor crude incidence rates/100,000 standard population [calculated from: [24,25]].
Indication Crude incidence rate (new cases/100,000 subjects)
Denmark Norway Sweden Finland Note
Pancreas 18.3 21.3 14.7 10.2 –
Mesotheliomaa 1.3 1.6 1.2b >1.0b Estimated incidence of mesothelioma was  not
available from Globocan [24]. In alternative,
the publication of Bianchi et al. was used [51].
Lung  69.6 39.3 48.5 34.9 –
Head & neck 29.0 18.0 17.8 17.0 –
Stomach 3.0 3.2 2.6 2.3 Incidence of gastric cancer was multiplied by
27%, the estimated frequency of HER2+ cases
[52].
Kidney 13.4 16.1 15.8 11.6 –
Melanoma 28.6 (14.3) 22.4 (11.2) 30.2 (15.1) 30.7 (15.3) Incidence rates in parenthesis are referred to
BRAF mutation, which represents about 50% of
melanomas [53].
a Statistics on mesothelioma not available from Globocan.
b Pleural mesothelioma only.
Table 3
Overall treatment costs, by therapy and country.
Therapy Denmark Norway Sweden Finland Average of the 4 Nordics
Total drug
costs (D )
Cost of
study drug
(% vs. total
drug
costs)a
Total drug
costs (D )
Cost of
study drug
(% vs. total
drug
costs)a
Total drug
costs (D )
Cost of
study drug
(% vs. total
drug
costs)a
Total drug
costs (D )
Cost of
study drug
(% vs. total
drug
costs)a
Total drug
costs (D )
Cost of study
drug (% vs. total
drug costs)a
Bevacizumab 17,928 90% 24,685 59% 18,969 91% 17,963 96% 19,886 82%
Cetuximab 23,509 96% 18,813 95% 22,916 96% 20,239 97% 21,369 96%
Erlotinib 6,808 93% 10,116 55% 7,427 85% 7,201 91% 7,888 78%
Ipilimumab 65,521 100% 62,406 100% 68,884 100% 68,882 100% 66,423 100%
Nab-paclitaxel 12,562 97% 14,625 73% 15,124 94% 14,943 96% 14,313 90%
Pemetrexed 16,285 99% 11,983 97% 17,171 98% 17,625 99% 15,766 98%
Ramucirumab (combination) 38,865 95% 43,458 81% 37,474 98% 36,718 99% 39,129 93%
Ramucirumab (monotherapy) 17,551 100% 16,854 100% 17,513 100% 17,362 100% 17,320 100%
S-1  1,840 93% 1,685 78% 1,900 84% 1,620 87% 1,761 86%
Temsirolimus 14,380 100% 13,618 100% 16,022 100% 15,757 100% 14,944 100%
Trastuzumab 19,485 95% 18,006 92% 21,708 98% 21,345 96% 20,136 95%
Vemurafenib 28,107 100% 25,984 100% 28,478 100% 22,477 100% 26,262 100%
a Since certain therapies are given in combination, they will account for a certain proportion of overall therapy costs. Drugs given as monotherapy account for the entire
therapy  costs (100%).
Table 4
Costs per month of overall survival, by therapy and country.
Therapy Indication Absolute
beneﬁt
(months)
Relative
beneﬁt (%)
Cost per month of OS (D /month)
Denmark Norway Sweden Finland Average of 4 Nordics
Bevacizumab Lung 2.0 19% 1,458 2,007 1,542 1,460 1,617
Cetuximab Head & neck 2.7 36% 2,328 1,863 2,269 2,004 2,116
Cyramza (alone) Stomach 1.4 37% 3,375 3,241 3,368 3,339 3,331
Cyramza (in association) Stomach 2.2 30% 4,048 4,527 3,904 3,825 4,076
Erlotinib Pancreas 0.4 7% 1,064 1,581 1,160 1,125 1,232
Ipilimumab Mesothel. 4.0 67% 6,552 6,241 6,888 6,888 6,642
Nab-paclitaxel Stomach 1.8 27% 1,478 1,721 1,779 1,758 1,684
Pemetrexed Stomach 2.8 30% 1,346 990 1,419 1,457 1,303
S-1  Stomach 0.7 9% 214 196 221 188 205
Temsirolimus Kidney 3.6 49% 1,319 1,249 1,470 1,446 1,371
e
c
d
F
1
+
d
vTrastuzumab Stomach (HER2+) 2.7 24% 
Vemurafenib Melanoma (BRAF) 3.90 40% 
Average  of products – 2.2 31% 
specially for cetuximab, nab-paclitaxel, pemetrexed and ramu-
irumab. For these cases, modiﬁcation of BSA or weight did
etermine the usage of more/less vials, compared to the base case.
or nab-paclitaxel, a 10% increase of the BSA (from 1.73 m2 to
.90 m2) practically did not modify cost per OS and PFS (variation:
0.36%, while a 10% decrease of the BSA) (from 1.73 m2 to 1.56 m2)
etermined a variation of −30.7% for the same outcome. Consistent
ariation of results were also observed under the assumption of no1,412 1,305 1,573 1,547 1,459
2,067 1,911 2,094 1,653 1,931
2,222 2,236 2,307 2,224 2,247
wastage. As expected, cost per month of OS and PFS decreased for all
drugs administered intravenously. Speciﬁcally for nab-paclitaxel,
the cost reduction from base case analysis was about 26%.4. Discussion
With the present analysis we aimed to address two  main topics.
First, we wanted to apply a simple quali-quantitative method to
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Table  5
Costs per month of progression free survival (D /month), by product and country.
Therapy Indication Absolute beneﬁt
(months)
Relative beneﬁt
(%)
Cost per month of PFS (D /month)
Denmark Norway Sweden Finland Average of 4 Nordics
Bevacizumab Lung 1.6 33% 2,801 3,857 2,964 2,807 3,107
Cetuximab Head & neck 2.3 70% 4,198 3,359 4,092 3,614 3,816
Erlotinib Pancreas 0.2 6% 1,815 2,698 1,980 1,920 2,103
Ipilimumab Melanoma 0.1 4% 22,909 21,820 24,085 24,084 23,225
Nab-paclitaxel Pancreas 1.8 49% 2,284 2,659 2,750 2,717 2,602
Pemetrexed Mesothel. 1.8 46% 2,857 2,102 2,102 3,092 2,538
Ramucirumab (combination) Stomach 1.5 52% 8,833 9,877 8,517 8,345 8,893
Ramucirumab (monotherapy) Stomach 0.8 62% 8,358 8,026 8,339 8,268 8,248
S-1  Stomach −0.7 −13% 383 351 396 338 367
Temsirolimus Kidney 1.9 100% 3,784 3,584 4,216 4,147 3,933
Trastuzumab Stomach (HER2+) 1.2 22% 2,908 2,688 3,240 3,186 3,005
Vemurafenib Melanoma (BRAF) 5.2 319% 4,091 3,782 4,145 3,272 3,823
Average of products – 1.5 62% 5,435 5,400 5,569 5,482 5,472
Note: N/A = not available.
Table 6
Results of sensitivity analysis.
Therapy Cost per month of OS (D /month)
Base case +10% BSA −10% BSA +10% weight −10% weight No wastage
Bevacizumab 1,617 1,636 1,597 1,801 1,525 1,550
Cetuximab 2,116 2,137 1,736 2,116 2,116 1,837
Erlotinib 1,232 1,242 1,212 1,232 1,232 1,019
Ipilimumab 6,642 6,642 6,642 8,303 6,642 6,476
Nab-paclitaxel 1,684 1,690 1,167 1,684 1,684 1,244
Pemetrexed 1,303 1,346 1,147 1,303 1,303 1,164
Ramucirumab (combination) 4,076 4,137 4,076 4,076 3,440 3,531
Ramucirumab (monotherapy) 3,331 3,331 3,331 3,331 2,771 2,882
S-1  205 225 185 205 205 193
Temsirolimus 1,371 1,371 1,371 1,371 1,371 1,143
Trastuzumab 1,459 1,466 1,454 1,459 1,459 996
Vemurafenib 1,931 1,931 1,931 1,931 1,931 1,931
Therapy Cost per month of PFS (D /month)
Base case +10% BSA −10% BSA +10% weight −10% weight No wastage
Bevacizumab 3,107 3,144 3,069 3,461 2,930 2,979
Cetuximab 3,816 3,855 3,132 3,816 3,816 3,313
Erlotinib 2,103 2,120 2,068 2,103 2,103 1,738
Ipilimumab 23,225 23,225 23,225 29,033 23,225 22,644
Nab-paclitaxel 2,602 2,612 1,803 2,602 2,602 1,922
Pemetrexed 2,538 2,631 2,239 2,538 2,538 2,471
Ramucirumab (combination) 8,893 9,026 8,893 8,893 7,506 7,703
Ramucirumab (monotherapy) 8,248 8,248 8,248 8,248 6,861 7,136
S-1  367 404 331 367 367 346
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3,8
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pTemsirolimus 3,933 3,933 
Trastuzumab 3,005 3,021 
Vemurafenib 3,823 3,823 
est whether the cost of a drug reﬂected its real clinical value, com-
aring pharmaceutical treatments approved for different oncology
ses. Then we wanted to test the method, analyzing the practical
ase of the comparison between nab-paclitaxel versus other phar-
acological treatments that could represent a good benchmark.
Regarding the ﬁrst topic, the analysis showed a good consis-
ency between the sustained cost per OS month for a drug, and
he relative OS increase offered by the drug vs. its trial compara-
or. According to this analysis, the higher is the clinical beneﬁt, the
igher is the cost per OS month, reﬂecting that budget holders in
ordic countries recognized consistently the value of the drugs. In
his analysis, there were not large deviations from the expected
rend. Unlike the OS analysis, the PFS analysis did not produce sim-
lar results, and the correlation between cost per PFS month and PFS
elative beneﬁt was mainly reduced by three drugs: ipilimumab,
emurafenib, ramucirumab. Ipilimumab was not associated to PFS
dvantage vs. trial comparator (2.86 months for ipilimumab; 2.76
lacebo months for placebo; [44]); vemurafenib was associated to33 3,933 3,933 3,277
95 3,005 3,005 2,052
23 3,823 3,823 3,823
a relevant, statistically signiﬁcant PFS advantage (6.9 months for
vemurafenib, vs. 1.6 months for placebo). Ramucirumab was  not
associated to a ≥0.25 Cook distance, however its cost per PFS month
was higher than expected (average of all observations), if correlated
to the relative PFS gain. These observations decreased the overall
goodness of regression; moreover, regardless of these drugs, the
relation between costs and PFS advantage was  less clear than the
OS relation, especially in certain countries (Norway and Sweden).
Several considerations can be made to explain this trend for the
PFS analysis. In the ipilimumab trial, for example, OS was the clini-
cally important and primary endpoint [44]. Likely, PFS could be an
un-appropriate indicator for this drug. As a matter of fact, European
Public Assessment Report does not report PFS data and clearly indi-
cates that, if tolerated, the 4-cycles treatment should be continued
and completed regardless of clinical response and early progres-
sion of the disease [29], suggesting that the drug could have a kind
of “delayed” effect, making PFS endpoint not extremely relevant.
As a matter of fact, ipilimumab was  the drug associated with the
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sig. 2. Costs per month of OS (D /month) vs. OS beneﬁt: average data of the four No
ize  of bubbles is proportional to incidence rates [Table 2].  = 10–20 cases per 100
Cost  per OS month was found statistically dependent on OS gain vs. trial comparat
ighest OS advantage. Vemurafenib showed clear advantages in
oth PFS and OS, but it should be mentioned that the drug works
nly in a subgroup of patients (BRAF mutation patients). Similarly,
rastuzumab, the other drug approved for use in a subpopulation
HER2+ gastric cancer) had a favorable ratio between costs and
linical beneﬁt.
Focusing on nab-paclitaxel analysis, the drug cost per month of
S and PFS shows an overall favorable proﬁle.
In our view, the quali-quantitative approach adopted in this
nalysis, with certain reﬁnements, can be transformed into a good
ool for decision makers to evaluate consistency of decisions across
ifferent oncology areas. Of course, the method cannot be consid-
red a pure quantitative tool to anchor pricing and reimbursement
ecisions, but it can deﬁnitely help to avoid inconsistencies in bud-
et allocation.
The major issue for such approach is to deﬁne the con-
itions/criteria to detect comparators for a certain therapies,
articularly when deciding on how to allocate healthcare funds.
n our analysis, we detected benchmarks for nab-paclitaxel using a
et of criteria (i.e. solid tumors, drugs predominantly used in naïve
atients, approved after year 2000, indicated in conditions asso-
iated to poor prognosis). We  considered such selection criteria
bjective and appropriate to reduce the potential heterogeneity
f comparisons. However, it could be argued that certain inclu-
ion criteria were not used at all (e.g. include/exclude therapies
ndicated in speciﬁc patients’ subgroups; include/exclude therapies
ased on the epidemiological impact of the associated condition).
n our view, a good compromise on the number of selection criteria
hould be made, in order to ensure that comparison would remainountries.
ersons/year.
valid and informative, and to keep a good number of therapies for
comparison
Our focus on objective criteria, such as median times-to-event,
may  introduce an oversimpliﬁcation of important considerations
in the selection of the most appropriate therapy: long-term sur-
vival beneﬁts in small patient groups are not included in the
analysis of medians of a patient population and underestimated
in this approach when compared to real-life clinical practice. An
evaluation of more comprehensive, and complex, health-economic
analysis and studies is required to fully evaluate the beneﬁt of
these therapies across all sub-groups of patients. Additional con-
siderations to opportunity costs and sensitivity analysis to address
uncertainty in calculations, for example, are not included in this
analysis but are standard to a thorough health-economic analysis.
In the present analysis, we  used incidence data to estimate the
potential patient population eligible for each treatment. Of course
this approach is not extremely accurate to determine the budget
impact associated to a certain therapy, as incidence and treatment
duration are only two  of the several factors determining the amount
of drug use. A substantial number of patients with metastatic dis-
ease will not receive any chemotherapy at all due to usually old age
or poor performance status [36–38]. On the other side, the more
accurate approach, which would consist in determining the num-
ber of treated patients using national drug consumptions, would be
equally difﬁcult to implement. In fact, this analysis would require
availability of national data, drug use during comparable peri-
ods of time (the use of a drug generally increases over time, and
changes according to the availability of therapeutic alternatives).
Finally, for certain therapies indicated for multiple conditions (e.g.
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Fig. 3. Costs per month of PFS (D /month) vs. PFS beneﬁt, average data of the four Nordic countries*.
Size  of bubbles is proportional to incidence rates [Table 2].  = 10–20 cases per 100,000 persons/year. *Calculated through robust regression.
Cost per PFS month was  found statistically dependent on PFS gain vs. trial comparator.
Fig. 4. Costs per month of OS (D /month) vs. OS absolute beneﬁt vs. trial comparator.
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Fig. 5. Costs per month of PFS (D /month) vs. PFS absolute beneﬁt vs. trial comparator.
Fig. 6. Costs per month of OS (D /month) vs. OS beneﬁt, by product and country.
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ize of bubbles is proportional to incidence rates [Table 2].  = 10–20 cases per 100
Cost  per PFS month was  found statistically dependent on PFS gain vs. trial compar
rastuzumab, bevacizumab) it would be necessary to stratify use by
ndication, which is almost impossible with current available data.
Other reﬁnements could increase the validity of this type of anal-
sis. First, cost of treatment could be adjusted by dose intensity. As
 matter of fact, in certain clinical trials, therapeutic dosage could
ave been decreased/increased to take into account risk-beneﬁt
actors. In the nab-paclitaxel pivotal trial, for example, dose inten-
ity was 81% [16]. This correction was not applied in our analysis,
s similar information was not available for all investigated thera-
ies, but this aspect could be taken into account for further research
sing this approach. Second, prices used in these analyses should
nclude all those forms of discounts/rebates (price-volume, cost
haring, payment by results agreements, etc.) that could affect costs
f treatment. Finally, a systematic approach collecting all published
vidence on a certain drug/indication, integrating or pooling clini-
al data with meta-analytic approaches, would make the analyses
ven more accurate, although this could affect its easiness-to-use.
Summarizing, we believe that decision making in healthcare,
nd speciﬁcally in oncology, is a very complicated process that can-
ot be converted into a “perfect” algorithm. Many factors related
o the individuality of a disease and to the clinical needs of patients
hat cannot be simply measured or calculated with formulas. How-
ver, analytical tools, such as the one we proposed, could simply
ffer an additional hint to take decisions or to make sure that the
ecision respects certain rules
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